Department of Health and Human Services Center for Drug Evaluation and Research Conclusions Regarding Risk of Acute MI: COX-2 Selective NSAIDs Celecoxib  200 mg: no apparent effect > 200 mg: probable increased risk Rofecoxib  25 mg: probable increased risk >25 mg: definite increased risk Risk begins early in therapy, and is apparent during days 1-30 of use Valdecoxib  20 mg: no apparent effect
{}